Abstracts Archive - Page 513 of 2425 - ACR Meeting Abstracts

Abstract Number: PP04 • ACR Convergence 2022
Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building
Kara Wada, The Ohio State University, Columbus, OH
Background/Purpose: After years of ignoring my dry eyes and mouth, unrelenting fatigue, and body pain, an off-the-cuff comment from my dental hygienist finally pushed me…
Abstract Number: 2258 • ACR Convergence 2022
Relative Frequencies of the Spectrum of MRI Lesions in the Sacroiliac Joints of Healthy Individuals and Patients with Non-Specific Back Pain: What Is the Impact of Increasing Age?
Ulrich Weber¹, Susanne Pedersen², Mikkel Østergaard³, Pedro Machado⁴, Xenofon Baraliakos⁵, Robert G Lambert⁶ and Walter P Maksymowych⁷, ¹Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ²Rigshospitalet, København, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴University College London, London, United Kingdom, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Previous studies of patients with axial spondyloarthritis (axSpA) have demonstrated that certain MRI structural lesions in the sacroiliac joints (SIJ), notably erosions, has high…
Abstract Number: PP22 • ACR Convergence 2022
Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance
Natasha Trehan¹ and Laurie Proulx², ¹Take a Pain Check Foundation, Markham, ON, Canada, ²Canadian Arthritis Patient Alliance, Ottawa, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis is a chronic disease that affects a child's school life and relationships, creating social isolation for youth and young adults. Take…
Abstract Number: PP16 • ACR Convergence 2022
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
Ashley Krivohlavek, Oklahoma City, OK
Background/Purpose: At age 12, I was diagnosed with psoriasis (PsO) followed by a diagnosis of psoriatic arthritis (PsA) at age 30. I'm now 38. In…
Abstract Number: 2243 • ACR Convergence 2022
Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica
Vibeke Strand¹, Jennifer Sloane Lazar², Michael C Nivens³, Jingdong Chao⁴, Stefano Fiore⁵, Angeliki Giannelou⁶, Lita Araujo⁷ and Jerome Msihid⁸, ¹Stanford University School of Medicine, Stanford, CA, ²Sanofi, Delray Beach, FL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, ⁴Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Hoboken, NJ, ⁷Sanofi, Cambridge, MA, ⁸Sanofi, Chilly-Mazarin, France
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in the elderly. The phase 3 SAPHYR trial (NCT03600818) assessed the efficacy and safety of…
Abstract Number: PP15 • ACR Convergence 2022
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
Laura Genoves, Arthritis Foundation, Bainbridge Island, WA
Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
Abstract Number: PP25 • ACR Convergence 2022
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
Shung Chiu¹ and Mei Nee Chiu², ¹Spondylitis Association of America, Ludhiana, Punjab, India, ²University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India
Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
Abstract Number: 2251 • ACR Convergence 2022
Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Matthew Baker¹, Yuhan Liu¹, Rong Lu¹, Janice Lin¹, Jason Melehani¹ and William Robinson², ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
Abstract Number: 2248 • ACR Convergence 2022
Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort
Gregory McDermott¹, Keigo Hayashi², Kazuki Yoshida¹, Matthew Moll¹, Michael Cho¹, Tracy Doyle¹, Paul Dellaripa¹, Rachel Putman¹, Raul San Jose Estepar¹, George Washko¹, Elizabeth Regan³, Hiroto Hatabu¹, Gary M Hunninghake¹, Edwin Silverman¹ and Jeffrey Sparks⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³National Jewish Health, Denver, CO, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Subpleural interstitial lung abnormalities (ILA) may be a form of subclinical or preclinical interstitial lung disease (ILD) and have been reported in up to…
Abstract Number: 2247 • ACR Convergence 2022
Priority Research Topics for Vaccine Uptake Among Adults with Autoimmune Conditions
Shilpa Venkatachalam¹, William Benjamin Nowell², Shubhasree Banerjee³, Kelly Gavigan⁴, Laura Stradford², Jennifer Gordon⁵, Lisa Emerich⁶, Hope Sullivan⁷, Ashira Blazer⁸, Brittany Banbury⁹, Vandana Dronadula¹, Kimberly Weaver¹⁰, Angela Degrassi⁴, Peter Merkel³, Robert McBurney¹¹, Mike Kappelman¹⁰, Jeffrey Curtis¹² and Michael George³, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Nyack, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Vasculitis Foundation, Philadelphia, ⁶iConquerMS, Waltham, MA, ⁷Inflammatory Bowel Disease (IBD) Partners, Chapel Hill, NC, ⁸Hospital for Special Surgery, New York, NY, ⁹NYU Langone, Fort Lee, NJ, ¹⁰School of Medicine, University of North Carolina (UNC), Chapel Hill, NC, ¹¹Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, ¹²University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Compared to the general population, adults living with autoimmune disease are at nearly twice the risk of vaccine-preventable infections, making this a high priority…
Abstract Number: 2246 • ACR Convergence 2022
Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on themes in rheumatoid arthritis (RA) patients' treatment goals which associated with aspects of rheumatology care such as presence of a…
Abstract Number: 1865 • ACR Convergence 2022
Internet-based Enrollment for Myositis Studies Utilizing Patient Self-reported Diagnostic Criteria
Raisa Lomanto Silva¹, Silvia Martinez Laverde¹, Siamak Moghadam-Kia¹, Nicole Neiman², Dana Ascherman³, Chester Oddis³ and Rohit Aggarwal⁴, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, Department of Medicine, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Recruitment is a major challenge in myositis clinical studies, which is hindered by the rarity and heterogeneity of the disease. Internet-based clinical studies using…
Abstract Number: 2242 • ACR Convergence 2022
Metabolomics-based Identification of Metabolic Dysfunction in Inclusion Body Myositis
Jemima Albayda¹, Cissy Zhang¹, Pratik Khare¹, Brittany Adler¹, Erika Darrah¹, Lisa Christopher-Stine¹, Thomas E Lloyd² and Anne Le¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sporadic Inclusion Body Myositis (IBM) is the most common myopathy over the age of 50 and is currently refractory to treatment. The pathogenesis of…
Abstract Number: 1863 • ACR Convergence 2022
Aromatase Inhibitor Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model
Nicholas Young¹, Kyle Jablonski¹, Courtney DeVries², Lai-Chu Wu³, Anna Bratasz², Maryam Lustberg⁴, Raquel Reinbolt¹ and Wael Jarjour², ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, OH, ³The Ohio State University Division of Rheumatology and Immunology, Columbus, OH, ⁴Smilow Cancer Hospital, New Haven, CT
Background/Purpose: Aromatase Inhibitors (AIs) block physiological estrogen (E2) production in peripheral tissues and are used clinically to reduce disease recurrences and improve overall survival rates…
Abstract Number: 1866 • ACR Convergence 2022
Polymyositis/Dermatomyositis Readmissions: Analysis of the Nationwide Readmission Database
Ehizogie Edigin¹, Amy Trang², Sandhya Shri Kannayiram³, Chinenye Osuorji⁴, Christopher Hino¹, Precious Eseaton⁵, Solomon Anighoro⁶, Augustine Manadan² and Christina Downey⁷, ¹Loma Linda University Health, Loma Linda, CA, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ⁴Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY, ⁵University of South Wales, Cardiff, Wales, United Kingdom, ⁶St. Helens and Knowsley Teaching hospitals NHS Trust, Prescot, England, United Kingdom, ⁷Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Polymyositis (PM)/ Dermatomyositis (DM) is a chronic immune-mediated myositis characterized by relapses that can lead to frequent hospitalizations. There is a scarcity of national…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].